Cingulate Inc (CING NASDAQ) stock market data APIs
$5.2139
-0.33(-6.3%)
as of July 18, 2025
Try our APIs with
free plan!
Cingulate Inc Financial Data Overview
Price chart is built with
Anychart
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company develops medications capable of once-daily dosing using its proprietary drug delivery platform technology, Precision Timed Release. Its drug candidates include CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials, as well as CTx-1302 (dextroamphetamine), which is in Phase 1/2 clinical pharmacology and Phase 3 clinical efficacy and safety trials for the treatment of ADHD in children, adolescents, and adults; and CTx-2103 (buspirone) that is in a formulation stage for the treatment of anxiety and related disorders. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Prev. Close
5.2139
Open
4.8888
High
5.2857
Low
4.8023
52 wk Range
1.8001-20.83
Market Cap
20 422 K
Shares Outstanding
4 246 K
EPS
-1.04
Beta
-0.861
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Cingulate Inc data using free add-ons & libraries
Get Cingulate Inc Fundamental Data
Cingulate Inc Fundamental data includes:
- Net Revenue:
- EBITDA: -15 748 010
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.94
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Cingulate Inc News
New
Cingulate names Nilay Patel as chief legal officer ahead of FDA filing
KANSAS CITY - Biopharmaceutical company Cingulate Inc. (NASDAQ:CING), a micro-cap firm valued at $19.15 million, has appointed Nilay Patel as Chief Legal Officer as the company prepares to submit a ne...
Cingulate Inc. Reports First Quarter 2025 Financial Results and Provides an Updated Timeline of Key Developments for its lead ADHD and Anxiety Assets
Pre-NDA Meeting for CTx-1301(dexmethylphenidate) Held April 2, 2025; New Drug Application Submission Targeted for Mid-2025 Non-Dilutive Funding to Accelerate Development of CTx-2103 (buspirone) KANS...
Cingulate Inc. Reports Full Year 2024, Fourth Quarter Results, and Provides Development Update on Major Milestones Achieved
In-Person FDA Meeting Scheduled for April 2; New Drug Application Submission Targeted for Mid-2025 $17.5 million increase in Working Capital; Cash Runway Extending into Q4, Well Beyond Target Date for...
Apple, Microsoft and AIG rise premarket; Marathon Digital falls
Investing.com -- U.S. futures traded largely unchanged Thursday, with investors largely shutting up shop as a positive year on Wall Street draws near to a close. Here are some of the biggest premarke...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
